The evidence showed that aberrant EGFR signaling increased the frequency of Treg cells in TIME by chemokine production, therefore EGFR inhibitors suppressed this process, improving the response of ICIs in NSCLC patients [35]. Here, EGFR is linked to non-small cell lung carcinoma.